摘要
目的:研究联合检测血清Mesothelin和CA125在上皮性卵巢癌诊断中的临床意义。方法:采用定量酶联免疫吸附试验(ELISA)检测上皮性卵巢癌患者31例,良性卵巢肿瘤32例和正常妇女30例血清中的Me-sothelin和CA125水平。结果:上皮性卵巢癌患者的Mesothelin水平明显高于良性卵巢肿瘤患者和正常对照组(P<0.01),良性卵巢肿瘤组患者与正常对照组的差异无显著性(P>0.05)。不同类型的上皮性卵巢癌的Mesothelin的差异无显著性(P>0.05)。Mesothelin和CA125联合检测对上皮性卵巢癌诊断的灵敏度和正确率明显高于单项检测CA125或Mesothelin(P值均<0.05)。结论:血清Mesothelin和CA125联合检测可提高上皮性卵巢癌的早期诊断率。
Objective:To determine the serum Mesothelin and CA125 in the diagnosis of ovarian cancer and analyze their clinical significance.Methods: The level of serum Mesothelin and CA125 was measured by ELISA including 31 ovarian cancer patients,32 benign ovarian tumor patients and 30 normal women.Results: Level of serum Mesothelin: ovarian cancer group was higher than that of the other two groups(P0.01),there was no significant difference between the other two groups(P0.05),also there was no significant difference among the dinfferent kinds of ovarian cancer(P0.05).Sensitivity and accuracy of the combination of serum Mesothelin and CA125 in ovarian cancer: were higher than detection of CA125 alone(P0.05),or Mesothelin alone(P0.05).Conclusion: The level of serum Mesothelin combined with CA125 can promote the diagnosis of ovarian cancer.
出处
《现代肿瘤医学》
CAS
2012年第1期138-140,共3页
Journal of Modern Oncology